North America Expansion Recent PharmaLegacy acquisition and the North American facility position BioLegacy as a bridge for global preclinical programs, enabling clients to access GLP and non GLP toxicology, pharmacokinetics, and IND enabling studies across continents.

Full Spectrum Preclinical The company's AAALAC accredited, USDA registered facility offers GLP and non GLP toxicology, pharmacokinetics, and NHP and large animal studies, providing a compliant, high quality partner for sponsors needing rigorous data.

IND Enablement Focus From early discovery through IND enabling research, BioLegacy offers development continuity, supporting faster regulatory readiness and reduced vendor handoffs.

Experienced BD Leadership A track record of senior business development and toxicology leadership indicates a proactive sales approach and established client relationships, presenting opportunities for strategic collaborations and multi study pipelines.

Mid Market Advantage With between 11 and 50 employees and revenue between 50 and 100 million USD, BioLegacy targets mid market biotech and pharma firms seeking scalable, reliable preclinical services.